1. HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome
- Author
-
Terence J. Hadley, Gary M. Troup, Kenneth J. Smith, Geetha Joseph, John W. Oldfather, Robert L. Barker, and Benjamin Djulbegovic
- Subjects
Adult ,Male ,Molecular Sequence Data ,Thrombotic thrombocytopenic purpura ,Pilot Projects ,Human leukocyte antigen ,Disease ,Polymerase Chain Reaction ,Pathogenesis ,Antigen ,hemic and lymphatic diseases ,Humans ,Medicine ,Retrospective Studies ,Base Sequence ,Purpura, Thrombotic Thrombocytopenic ,business.industry ,Histocompatibility Testing ,Homozygote ,Retrospective cohort study ,DNA ,HLA-DR Antigens ,Hematology ,medicine.disease ,HLA-DR53 ,Relative risk ,Hemolytic-Uremic Syndrome ,Immunology ,Female ,Disease Susceptibility ,business ,HLA-DRB4 Chains - Abstract
Class I and Class II HLA antigens were tested in patients treated for thrombotic thrombocytopenic purpura or hemolytic uremic syndrome (TTP/HUS) to determine whether there is a disease association. Based on the results of a pilot trial, retrospective HLA-typing of 18 patients with a diagnosis of TTP/HUS and prospective typing of 12 newly diagnosed patients with TTP/HUS were performed. Twenty-one patients were non-Hispanic Caucasians, 7 were African-Americans, and 2 were Hispanic-Caucasians. Of 30 patients tested, 28 were positive for DR52 (chi-squared = 5.14, P < 0.05), and only two were positive for DR53 compared to 57% of controls (chi-squared = 18.5, P < 0.0005). Diverse DR52 subtypes (DRB3*0101, DRB3*02, and DRB3*0301) were found by oligonucleotide testing in 15 patients, suggesting the association was not with DR52 but with absence of the DR53 antigen. The 2 patients with DR53 were not homozygous. This study suggests that the supertypic antigen, DR53, may govern susceptibility to TTP/HUS, since the relative risk of this disease among DR53 positives is reduced at 0.09 (95% confidence interval, 0.01-0.28). This finding indicates a possible immunogenetic component in the pathogenesis of TTP.
- Published
- 1994
- Full Text
- View/download PDF